Hepatitis C virus inhibitors having the general formula (I)
are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.